Intelligence Profile
Clinical Applications
Limited clinical evidence available
The combination of Ipamorelin + CJC-1295 + IGF-1 LR3 is primarily used off-label, with applications centered around growth hormone and IGF-1 pathway modulation. However, clinical evidence for this specific combination is extremely limited.
Reported Uses
Based on available literature, this peptide combination is used for:
- Performance enhancement - Athletes and fitness enthusiasts use these compounds with the goal of increasing muscle mass and improving recovery
- Anti-aging applications - Some practitioners prescribe these peptides for age-related decline in growth hormone levels
- Body composition goals - Users seek potential benefits for fat loss and lean muscle development
Evidence Limitations
The 2026 review in Frontiers in Endocrinology highlights a significant gap between clinical evidence and actual patient use of GH-IGF1 axis peptides. Key limitations include:
- No dedicated clinical trials were found specifically testing this three-compound combination
- Most evidence comes from individual peptide studies rather than combination therapy
- Patient self-administration often occurs without adequate clinical oversight
- Long-term safety data for this combination is lacking
Clinical Considerations
The literature emphasizes that while these peptides target well-understood physiological pathways (growth hormone release and IGF-1 signaling), their combined use represents an area where practice has outpaced rigorous clinical validation.
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a qualified healthcare provider before considering any peptide therapy, as individual responses and safety profiles can vary significantly.